Scott Stephens

Ever since 2023, a class of GPL-1 based drugs — which for two decades were used to treat type 2 diabetes — have been heralded as a “revolution in weight loss” and signalling the “end of obesity”. While these drugs go by different names, they’ve become popularly grouped under the shorthand “Ozempic”. It’s no exaggeration to say that Ozempic has become a cultural phenomenon. Millions of people in the United States, Australia, South Korea, the UK, the EU take semaglutide injections, not to treat diabetes, but in order to reduce their hunger and eliminate what is sometimes called “food noise”. Obesity has long been moralised — associated with laziness, ill-disciplined eating, poor diet, a general lack of self-control. But expensive weight loss drugs like Ozempic have, to date, exacerbated the class dimension of obesity. This was nicely captured in a 2024 South Park episode (called “The End of Obesity”), in which Cartman is denied a prescription because the drug isn’t covered by